G1 Therapeutics Inc (NAS:GTHX)
$ 7.15 0 (0%) Market Cap: 377.22 Mil Enterprise Value: 364.45 Mil PE Ratio: 0 PB Ratio: 15.31 GF Score: 31/100

G1 Therapeutics Inc at UBS Global Healthcare Conference Transcript

May 21, 2019 / 08:00PM GMT
Release Date Price: $23.24 (+3.06%)
Unidentified Analyst

Good afternoon and thank you for coming to the 2019 UBS Global Healthcare Conference. My name is [Brandon], and I'm happy to be your host for this session. Our next presenter is Mark Velleca, CEO of G1 Therapeutics. Following this session, there will be a breakout session in the [Euris] Room. Thank you.

Mark A. Velleca
G1 Therapeutics, Inc. - CEO, President & Director

Thank you, [Brandon]. Appreciate the opportunity to share the G1 Therapeutic story with all of you here today in New York City. Also would like to welcome those joining via webcast. G1 is at an important inflection point. We're preparing marketing applications for our first investigational therapy, trilaciclib, and anticipate significant milestones later this year for our next 2 therapies, lerociclib and G1T48.

To remind you, I'll be making forward looking statements today. Our 3 therapeutic candidates address the most common forms of cancer, and our vision is to improve the lives of people affected by these tumors. We've proven our ability to operate in a capital

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot